BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23911682)

  • 61. Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.
    Tseng WH; Liu CL; Huang SK; Liao AC; Kuo JR; Hun SH; Chen CH; Su CC; Wang JC; Lee KH; Shen KH; Li CF
    Int Urol Nephrol; 2019 Aug; 51(8):1335-1342. PubMed ID: 31129781
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices.
    Sountoulides P; Mutomba WF; Bouras E; Lim J; Bourdoumis A; Jain A
    Urologia; 2020 Aug; 87(3):142-148. PubMed ID: 31959070
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Impact of operator experience on TURB of high-grade non-muscle-invasive bladder cancer--analysis of 254 second resections at a university teaching hospital].
    Lazica DA; Degener S; Böttcher S; Brandt AS; Störkel S; Roth S
    Aktuelle Urol; 2013 May; 44(3):196-200. PubMed ID: 23712276
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor.
    Kim W; Song C; Park S; Kim J; Park J; Kim SC; Cho YM; Hong B; Ahn H
    J Endourol; 2012 Aug; 26(8):1059-64. PubMed ID: 22390720
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.
    Akand M; Muilwijk T; Raskin Y; De Vrieze M; Joniau S; Van Der Aa F
    Clin Genitourin Cancer; 2019 Aug; 17(4):e784-e792. PubMed ID: 31097388
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic factors of early second transurethral resection of non-muscle invasive bladder cancer 10 years of experience of a referral center.
    Žemličková B; Brisuda A
    Rozhl Chir; 2022; 101(3):119-128. PubMed ID: 35387468
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Analysis of 34 cases of infiltrating carcinoma of the bladder treated exclusively with partial cystectomy (part 1)].
    Escudero Barrilero A; Fernández Fernández E; Jiménez Cidre M; Maganto Pavón E; Mayayo Dehesa T; Rodríguez Rodríguez R; Galvis San Juan F; Burgos Revilla FJ
    Arch Esp Urol; 1996 May; 49(4):349-64. PubMed ID: 8754191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
    Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
    Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
    Segal R; Yafi FA; Brimo F; Tanguay S; Aprikian A; Kassouf W
    BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study.
    Jaidane M; Bouicha T; Slama A; Hmida W; Hidoussi A; Ben Sorba N; Mosbah F
    Urology; 2010 Jun; 75(6):1392-5. PubMed ID: 19781747
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series.
    Gendy R; Delprado W; Brenner P; Brooks A; Coombes G; Cozzi P; Nash P; Patel MI
    BJU Int; 2016 Apr; 117 Suppl 4():54-9. PubMed ID: 26486968
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function.
    Davila HH; Weber T; Burday D; Thurman S; Carrion R; Salup R; Lockhart JL
    BJU Int; 2007 Nov; 100(5):1026-9. PubMed ID: 17868423
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.
    Yoshii H; Ito K; Asano T; Horiguchi A; Hayakawa M; Asano T
    Oncol Rep; 2013 Sep; 30(3):1073-80. PubMed ID: 23817592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.